Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 10/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317510 | 0.91 | — | — | |
| SCHEMBL25194078 | 0.79 | — | — | |
| SCHEMBL142616 | 0.76 | — | — | |
| SCHEMBL129150 | 0.71 | — | — | |
| SCHEMBL2517620 | 0.71 | CXCR4 (0.50) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 | |
| SCHEMBL472132 | 0.71 | CXCR4 (0.89) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 | |
| SCHEMBL316126 | 0.71 | CXCR4 (0.89) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 | |
| SCHEMBL623920 | 0.71 | — | — | |
| SCHEMBL11232630 | 0.71 | CXCR4 (0.89) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 | |
| SCHEMBL11235838 | 0.71 | CXCR4 (0.89) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991980-B1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-9790212-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| EP-3019494-B1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD (GB) | 2017-06-21 | — | — | EP | disclosed |
| US-20170029412-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | US | disclosed |
| US-9556157-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-9505745-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-29 | — | — | US | disclosed |
| US-9382234-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160130261-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-20160102083-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | CXCR4 2808/4885SMN1; SMN2 2218/4885ALDH1A1 2517/4885 |
| US-20160102083-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | CXCR4 2808/4885SMN1; SMN2 2218/4885ALDH1A1 2517/4885 |
| US-20170029412-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | CXCR4 2808/4885SMN1; SMN2 2218/4885ALDH1A1 2517/4885 |
| US-20160130261-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | CXCR4 2808/4885SMN1; SMN2 2218/4885ALDH1A1 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.